Orthofix Medical Inc.
NASDAQ•OFIX
CEO: Mr. Geoffrey C. Gillespie
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 1992-04-24
Orthofix Medical Inc. operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions. This segment also designs, develops, and markets a portfolio of navigation technologies, including tracked surgical tools, intelligent software, and imaging equipment based on machine-vision and optical innovations. The Global Orthopedics segment offers products and solutions that allow physicians to treat various orthopedic conditions related to limb reconstruction and deformity correction unrelated to the spine. This segment designs, develops, and markets external and internal fixation orthopedic products that are coupled with enabling digital technologies to serve the complete patient treatment pathway. It sells its products through distributors and sales representatives to hospitals, healthcare organizations, and healthcare providers. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.
Contact Information
Market Cap
$556.38M
P/E (TTM)
-4.7
32.4
Dividend Yield
--
52W High
$20.48
52W Low
$10.24
52W Range
Rank38Top 36.9%
4.3
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 4.3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q3 2025 Data
Revenue
$205.63M+4.59%
4-Quarter Trend
EPS
-$0.57-19.72%
4-Quarter Trend
FCF
$2.50M-57.37%
4-Quarter Trend
2025 Q3 Earnings Highlights
Key Highlights
Reported Net Sales Growth Q3 reported net sales totaled $205.6M USD, reflecting 4.6% growth versus prior year period.
Gross Profit Increased 10% Quarterly gross profit reached $148.5M USD, marking a strong 10.0% increase compared to 2024.
EBITDA Margin Expansion Non-GAAP pro forma adjusted EBITDA was $24.6M USD, with margin expanding approximately 233 basis points.
Orthopedics Segment Sales Global Orthopedics segment sales reached $33.6M USD for the quarter, achieving 10.1% reported growth.
Risk Factors
Executive Arbitration Accrual Recorded $18.3M accounting accrual reflecting estimated value of severance/equity rights related to executive arbitration.
M6 Product Line Impairment Recognized $32.2M loss on M6 inventories and long-lived assets impairment during the nine months ended September 30.
SG&A Expense Driven by Legal SG&A increased $18.0M for the quarter, driven primarily by $13.2M associated with ongoing legal matters costs.
Outlook
Debt Covenant Compliance Maintained Confirmed compliance with all required debt-to-EBITDA leverage ratio covenants as of September 30, 2025.
Inventory Efficiency Improved Inventory turns improved to 1.5 times compared to 1.2 times reported in the prior year period.
New Tax Disclosure Adopted Adopted ASU 2023-09 standard for income tax disclosures, effective prospectively starting January 1, 2025.
Peer Comparison
Revenue (TTM)
$844.60M
$818.06M
AVNS$699.90M
Gross Margin (Latest Quarter)
KALV91.0%
79.8%
72.2%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| SVRA | $1.18B | -10.9 | -86.6% | 21.2% |
| BFLY | $1.05B | -13.1 | -37.8% | 7.3% |
| KALV | $737.98M | -3.7 | -282.0% | 44.0% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-1.6%
Flat Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
75%
Volatile Cash Flow
Research & Insights
Next earnings:Feb 24, 2026
EPS:$0.44
|Revenue:-
Reports
All Years
Form 10-Q - Q3 2025
Period End: Sep 30, 2025|Filed: Nov 4, 2025|Revenue: $205.63M+4.6%|EPS: $-0.57-19.7%MissForm 10-Q - Q2 2025
Period End: Jun 30, 2025|Filed: Aug 5, 2025|Revenue: $203.12M+2.3%|EPS: $-0.36-59.1%BeatForm 10-Q - Q1 2025
Period End: Mar 31, 2025|Filed: May 6, 2025|Revenue: $193.65M+2.7%|EPS: $-1.35+42.1%MissForm 10-K - FY 2024
Period End: Dec 31, 2024|Filed: Feb 25, 2025|Revenue: $799.49M+7.1%|EPS: $-3.30+19.9%MissForm 10-Q - Q3 2024
Period End: Sep 30, 2024|Filed: Nov 7, 2024|Revenue: $196.61M+6.8%|EPS: $-0.71-7.8%MissForm 10-Q - Q2 2024
Period End: Jun 30, 2024|Filed: Aug 6, 2024|Revenue: $198.62M+6.2%|EPS: $-0.88-17.8%MissForm 10-Q - Q1 2024
Period End: Mar 31, 2024|Filed: May 7, 2024|Revenue: $188.61M+7.7%|EPS: $-0.95-44.4%MissForm 10-K - FY 2023
Period End: Dec 31, 2023|Filed: Mar 5, 2024|Revenue: $746.64M+62.1%|EPS: $-4.12-320.4%Miss